Current Research
Find out more about taking part in one of our studies
Find out more about taking part in an intervention treatment trial where you may receive a new treatment being tested for T1D. We also have information on monitoring trials where data is collected but there is no intervention/treatment and also information on screening for T1D. Screening studies are also available which can identify people who may be at risk of developing T1D
✅ Currently recruiting
The FABULINUS Study is testing an investigational study drug in people recently diagnosed with type 1 diabetes (T1D). Our goal is to see if the investigational study drug can help people with T1D to better manage their glucose levels.
✅ Currently recruiting
A randomised, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)
⚠️ Paused to recruitment
An adaptive platform trial by INNODIA – A randomised, adaptive, open label, parallel group, multi-centre platform trial in adults with newly diagnosed type 1 diabetes.
Would you like to be involved in studies where you have more monitoring, so that researchers can find out more about type 1 diabetes?
A research project for children and adults aged 1 or older and newly diagnosed with type 1 diabetes (within the last 6 months), to collect information about their diabetes, and inform them about other opportunities to take part in type 1 diabetes research. Siblings can help too.
Currently running
Treg-sparing co-stimulation blockade: testing a novel method for monitoring an immunosuppression strategy in people with Type 1 diabetes.
Research Study screening for risk of type 1 diabetes in adults aged 18-70 years.
A study to identify people who are at increased risk of developing T1D and monitor them for two years to see who progresses to T1D.
The ELSA Study is screening children aged from 3-13 years to determine their risk of developing type 1 diabetes.
Recruitment closed
A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preservation of beta-cell function (Ver-A-T1D)
Recruitment closed
Can a remotely monitored, home-based exercise intervention for individuals with type-one diabetes reduce immune driven disease activity? (EXTOD-Immune)
Recruitment closed
Trial of a new medication in people with 1 diabetes aged 5-25. Screening visit to be conducted within 9 weeks of diagnosis.
Recruitment closed
Trial of a new medication in people with 1 diabetes aged 18-44. Screening visit to be conducted within 9 weeks of diagnosis.
Recruitment closed
Study of safety and efficacy of CFZ533 in children and young adults with new onset type 1 diabetes.
Recruitment closed
Remote study investigating the progression of Type 1 diabetes in adults (18 years and over) within 120 days of diagnosis and insulin treated.
Recruitment closed
A project throughout Europe which collects blood samples and data from newly diagnosed patients between 1 and 45 years who have been diagnosed with type 1 diabetes within the previous 6 weeks and their first degree relatives (brothers, sisters, parents or children).
Recruitment closed
The PROTECT Study is testing how well an investigational medicine works in children and adolescents with Type 1 diabetes (T1D).
Recruitment closed
ITAD is a multicentre, randomised, double-blind, placebo-controlled clinical trial of to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes.
Recruitment closed
Trial of a new medication in 12-18 year olds with Type 1 diabetes within 100 days of diagnosis
Recruitment closed
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes.
Recruitment closed
This study aims to gain a better understanding of the immune processes that lead to the destruction of insulin producing beta cells.
Recruitment closed
This study will investigate if a new drug Anti-IL-21 when given together with another drug marketed for type 2 diabetes called liraglutide can preserve the beta cells in subjects diagnosed with type 1 diabetes.